Semaglutide

Generic Name
Semaglutide
Brand Names
Ozempic, Rybelsus, Wegovy
Drug Type
Small Molecule
Chemical Formula
C187H291N45O59
CAS Number
910463-68-2
Unique Ingredient Identifier
53AXN4NNHX
Background

Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...

Indication

Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...

Associated Conditions
BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
Associated Therapies
Chronic Weight Management therapy
Clinical Trials
Related News

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Phase 4
Completed
Conditions
Psoriasis Vulgaris
Diabetes Type 2
Interventions
Drug: Semaglutide
First Posted Date
2024-06-26
Last Posted Date
2024-07-01
Lead Sponsor
University of Banja Luka
Target Recruit Count
30
Registration Number
NCT06475586
Locations
🇧🇦

University of Banja Luka, Faculty of Medicine, Banja Luka, Bosnia and Herzegovina

The Effects of Semaglutide on Body Composition and Performance in Military Personnel

Phase 4
Not yet recruiting
Conditions
Obesity
Interventions
Drug: Semaglutide
First Posted Date
2024-06-21
Last Posted Date
2024-06-21
Lead Sponsor
United States Army Research Institute of Environmental Medicine
Target Recruit Count
144
Registration Number
NCT06468748

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

First Posted Date
2024-06-06
Last Posted Date
2024-10-03
Lead Sponsor
Scholar Rock, Inc.
Target Recruit Count
100
Registration Number
NCT06445075
Locations
🇺🇸

ProSciento CRU, Chula Vista, California, United States

🇺🇸

AdventHealth Translational Research Institute, Orlando, Florida, United States

🇺🇸

Great Lakes Clinical Trials, LLC d/b/a Flourish Research, Chicago, Illinois, United States

and more 4 locations

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

First Posted Date
2024-05-10
Last Posted Date
2024-12-04
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
240
Registration Number
NCT06409130
Locations
🇧🇬

UMHAT "Sv. Ivan Rilski", Clinic of Gastroenterology, Sofia, Bulgaria

🇧🇬

UMHAT Aleksandrovska, Sofia, Bulgaria

🇧🇬

"DCC XX - Sofia" EOOD, Sofia, Bulgaria

and more 94 locations

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

First Posted Date
2024-05-08
Last Posted Date
2024-05-28
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
150
Registration Number
NCT06403761
Locations
🇩🇪

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

First Posted Date
2024-05-02
Last Posted Date
2024-10-02
Lead Sponsor
Western University, Canada
Target Recruit Count
60
Registration Number
NCT06396416
Locations
🇨🇦

London Health Sciences Centre, London, Ontario, Canada

The Effect of Weekly Semaglutide Treatment on Energy Expenditure

Not Applicable
Recruiting
Conditions
Obesity; Drug
Interventions
Drug: Placebo
Drug: Semaglutide
First Posted Date
2024-04-30
Last Posted Date
2024-04-30
Lead Sponsor
Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences
Target Recruit Count
60
Registration Number
NCT06390501
Locations
🇨🇳

Shenzhen Institute of Advanced Technology, Shenzhen, China

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
Drug: Placebo
Drug: Cagrilintide
Drug: Semaglutide
First Posted Date
2024-04-29
Last Posted Date
2024-12-02
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
300
Registration Number
NCT06388187
Locations
🇺🇸

Aurora FDRC Inc., Costa Mesa, California, United States

🇺🇸

Clinical Trial Res Assoc,Inc, Plantation, Florida, United States

🇺🇸

Midwest Inst For Clin Res, Indianapolis, Indiana, United States

and more 21 locations

Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

First Posted Date
2024-04-12
Last Posted Date
2024-04-12
Lead Sponsor
Capital Medical University
Target Recruit Count
74
Registration Number
NCT06361823

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Withdrawn
Conditions
Metabolic Health
First Posted Date
2024-04-09
Last Posted Date
2024-04-09
Lead Sponsor
CorEvitas
Registration Number
NCT06354101
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy